The upregulation of the NO/sGC/cGMP pathway in arterial hypertension has been identified as a promising therapeutic goal for lowering blood pressure and reducing associated complications related to heart and kidney function based on experimental models of hypertension and NOS-inhibition without causing tolerance [18,19,39]. Here, NOS2 is linked to hypertensive disorder.